explore -WSS

explore

author：entertainment 2025-09-27 15:35:35 - browse：1957

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： STAT Report: Patient voices and perspectives

WSS

After traumatic brain injury, life support decisions can use more time

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Device maker Teleflex to acquire urology company for $600M

Key Senate committee drafts bipartisan bill to stem drug shortages

entertainment

explore

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Former reverend arrested for allegedly killing 8

Trump demands the U.S. pay no more for drugs than other countries … again

Exact Sciences stock tumbles despite strong cancer detection sales

Hepatitis C has a cure — but many Americans still lack access to it

Cue Health's Covid

23andMe had bad news about my health. I wish a person had delivered it

UnitedHealth financials solid despite Change Healthcare cyberattack

Medicare proposal to cover medical devices draws a mixed reaction

MultiPlan and major insurers sued for alleged medical price

explore

More tobacco lobbyists active in statehouses

After traumatic brain injury, life support decisions can use more time

STAT Report: Patient voices and perspectives

A new crop of companies is reshaping the health data economy

Medical bills so high, Medicare adding extra digits to claim forms

Why patients can’t get everything they want on drug pricing

entertainment

leisure time

hotspot

focus